These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 22550026)
41. Probing the nature of interactions in SH2 binding interfaces--evidence from electrospray ionization mass spectrometry. Chung EW; Henriques DA; Renzoni D; Morton CJ; Mulhern TD; Pitkeathly MC; Ladbury JE; Robinson CV Protein Sci; 1999 Oct; 8(10):1962-70. PubMed ID: 10548041 [TBL] [Abstract][Full Text] [Related]
42. Molecular recognition by SH2 domains. Bradshaw JM; Waksman G Adv Protein Chem; 2002; 61():161-210. PubMed ID: 12461824 [TBL] [Abstract][Full Text] [Related]
43. Structure and Dynamics of Drk-SH2 Domain and Its Site-Specific Interaction with Sev Receptor Tyrosine Kinase. Sayeesh PM; Iguchi M; Inomata K; Ikeya T; Ito Y Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928093 [TBL] [Abstract][Full Text] [Related]
44. Electrostatic interactions in the reconstitution of an SH2 domain from constituent peptide fragments. Ojennus DD; Lehto SE; Wuttke DS Protein Sci; 2003 Jan; 12(1):44-55. PubMed ID: 12493827 [TBL] [Abstract][Full Text] [Related]
45. Defining the specificity space of the human SRC homology 2 domain. Huang H; Li L; Wu C; Schibli D; Colwill K; Ma S; Li C; Roy P; Ho K; Songyang Z; Pawson T; Gao Y; Li SS Mol Cell Proteomics; 2008 Apr; 7(4):768-84. PubMed ID: 17956856 [TBL] [Abstract][Full Text] [Related]
46. A novel disulfide bond in the SH2 Domain of the C-terminal Src kinase controls catalytic activity. Mills JE; Whitford PC; Shaffer J; Onuchic JN; Adams JA; Jennings PA J Mol Biol; 2007 Feb; 365(5):1460-8. PubMed ID: 17137590 [TBL] [Abstract][Full Text] [Related]
47. Side-chain dynamics of the SAP SH2 domain correlate with a binding hot spot and a region with conformational plasticity. Finerty PJ; Muhandiram R; Forman-Kay JD J Mol Biol; 2002 Sep; 322(3):605-20. PubMed ID: 12225753 [TBL] [Abstract][Full Text] [Related]
48. Synthesis and evaluation of phosphopeptides containing iminodiacetate groups as binding ligands of the Src SH2 domain. Ye G; Schuler AD; Ahmadibeni Y; Morgan JR; Faruqui A; Huang K; Sun G; Zebala JA; Parang K Bioorg Chem; 2009 Aug; 37(4):133-42. PubMed ID: 19539345 [TBL] [Abstract][Full Text] [Related]
49. An investigation of phosphopeptide binding to SH2 domain. Lee JK; Moon T; Chi MW; Song JS; Choi YS; Yoon CN Biochem Biophys Res Commun; 2003 Jun; 306(1):225-30. PubMed ID: 12788092 [TBL] [Abstract][Full Text] [Related]
50. NMR dynamics-derived insights into the binding properties of a peptide interacting with an SH2 domain. Finerty PJ; Mittermaier AK; Muhandiram R; Kay LE; Forman-Kay JD Biochemistry; 2005 Jan; 44(2):694-703. PubMed ID: 15641795 [TBL] [Abstract][Full Text] [Related]
51. Differential recognition of syk-binding sites by each of the two phosphotyrosine-binding pockets of the Vav SH2 domain. Chen CH; Piraner D; Gorenstein NM; Geahlen RL; Beth Post C Biopolymers; 2013 Nov; 99(11):897-907. PubMed ID: 23955592 [TBL] [Abstract][Full Text] [Related]
53. The SH2 domain interaction landscape. Tinti M; Kiemer L; Costa S; Miller ML; Sacco F; Olsen JV; Carducci M; Paoluzi S; Langone F; Workman CT; Blom N; Machida K; Thompson CM; Schutkowski M; Brunak S; Mann M; Mayer BJ; Castagnoli L; Cesareni G Cell Rep; 2013 Apr; 3(4):1293-305. PubMed ID: 23545499 [TBL] [Abstract][Full Text] [Related]
54. Direct observation of protein-ligand interaction kinetics. Mittag T; Schaffhausen B; Günther UL Biochemistry; 2003 Sep; 42(38):11128-36. PubMed ID: 14503863 [TBL] [Abstract][Full Text] [Related]
55. Survey of solution dynamics in Src kinase reveals allosteric cross talk between the ligand binding and regulatory sites. Tong M; Pelton JG; Gill ML; Zhang W; Picart F; Seeliger MA Nat Commun; 2017 Dec; 8(1):2160. PubMed ID: 29255153 [TBL] [Abstract][Full Text] [Related]
56. Molecular rulers: an assessment of distance and spatial relationships of Src tyrosine kinase Sh2 and active site regions. Profit AA; Lee TR; Niu J; Lawrence DS J Biol Chem; 2001 Mar; 276(12):9446-51. PubMed ID: 11118446 [TBL] [Abstract][Full Text] [Related]
57. Hierarchy of simulation models in predicting structure and energetics of the Src SH2 domain binding to tyrosyl phosphopeptides. Verkhivker GM; Bouzida D; Gehlhaar DK; Rejto PA; Schaffer L; Arthurs S; Colson AB; Freer ST; Larson V; Luty BA; Marrone T; Rose PW J Med Chem; 2002 Jan; 45(1):72-89. PubMed ID: 11754580 [TBL] [Abstract][Full Text] [Related]
58. Selective inhibition of Src SH2 by a novel thiol-targeting tricarbonyl-modified inhibitor and mechanistic analysis by (1)H/(13)C NMR spectroscopy. Sundaramoorthi R; Siedem C; Vu CB; Dalgarno DC; Laird EC; Botfield MC; Combs AB; Adams SE; Yuan RW; Weigele M; Narula SS Bioorg Med Chem Lett; 2001 Jul; 11(13):1665-9. PubMed ID: 11425533 [TBL] [Abstract][Full Text] [Related]
59. An SH2 domain-based tyrosine kinase assay using biotin ligase modified with a terbium(III) complex. Sueda S; Shinboku Y; Kusaba T Anal Sci; 2013; 29(5):491-7. PubMed ID: 23665620 [TBL] [Abstract][Full Text] [Related]
60. Absolute quantification of phosphorylation on the kinase activation loop of cellular focal adhesion kinase by stable isotope dilution liquid chromatography/mass spectrometry. Ciccimaro E; Hanks SK; Yu KH; Blair IA Anal Chem; 2009 May; 81(9):3304-13. PubMed ID: 19354260 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]